Volume : 11, Issue : 12, December – 2024
Title:
THE COST-EFFECTIVENESS ANALYSIS AND DRUG USE TREND OF THE MOST COMMONLY USED ANTIBIOTICS IN SAUDI ARABIA
Authors :
Ramy Abdallah , Aminah Almadani , Salem Bahwireth , Yazan Alyamani ,Faisal Alhoubani , Hanouf Alsulami, Lama Alsobhi
Abstract :
Aim: Antibiotic drug resistance can result from the inappropriate use of antibiotics, which is a global concern. The purpose of this study was to evaluate the cost-effectiveness and pattern of drug use. To encourage their sensible use, studies are carried out to examine the pattern of antibiotic prescriptions, their adherence to accepted practices, and the financial impact on the patients.
Method: The study was intended to be a cross-sectional, single-center retrospective pharmacy database investigation of cost-utility relationships for the five most widely prescribed antibiotics in Saudi Arabia. The study included data spanning from January 1, 2019, to December 31, 2019. Frequencies and percentages of the demographic traits were displayed, together with the Wilson 95% confidence intervals for the proportions. The adherence of Saudi Arabia’s antibiotic prescription practices to the National Antimicrobial Guidelines was compared using the chi-square test (for P-value computation).
Results: The highest percentage of patients (35.97%) came from the 18–35 age group, and the lowest percentage (1.82%) was from the 72–88 age group. The greatest number of units administered was 22487 for amoxicillin and clavulanic acid, which was given to 42.93% of patients; the lowest number was 8.04% for ciprofloxacin (4215). Cefdenir had the longest therapeutic duration (7.23 days), while azithromycin had the shortest length (3.58 days). Cefdenir 38.66SR (10.31 USD) had the highest cost, while Cefuroxime 12.43SR (3.31 USD) had the lowest estimated cost.
Conclusion: Because of their broad spectrum of activity against a variety of microorganisms, our study found that amoxicillin and clavulanic acid were the most commonly utilized first-line medicines in the treatment of bacterial infections.
Before prescribing, laboratory testing to determine the type of bacterium could stop the emergence of medication resistance and preserve the antibiotic for later use. For any indication that might encourage the prudent use of antibiotics, cost-benefit analyses of the medications must be carried out.
Cite This Article:
Please cite this article in press Ramy Abdallah et al., The Cost-Effectiveness Analysis And Drug Use Trend Of The Most Commonly Used Antibiotics In Saudi Arabia. .,Indo Am. J. P. Sci, 2024; 11 (12).
Number of Downloads : 10
References:
1. Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. Mayo Clin Proc 2011; 86: 156–67. https://doi.org/10.4065/mcp.2010.0639
2. Knight GM, Costelloe C, Murray KA et al. Addressing the unknowns of antimicrobial resistance: quantifying and mapping the drivers of burden. Clin Infect Dis 2018; 66: 612–6. https://doi.org/10.1093/cid/cix765
3.Global Action Plan on Antimicrobial Resistance. http://www.wpro.who.int/entity/drug_resistance/resources/global_action_plan_eng.pdf (15August 2020, date last accessed).
4. Coates A, Hu Y, Bax R et al. The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov 2002; 1: 895–910. https://doi.org/10.1038/nrd940
5. Etebu E, Arikekpar I. Antibiotics: classification and mechanisms of action with emphasis on molecular perspectives. IJAMBR 2016; 4: 90–101. https://doi.org/10.33500/ijambr.2016.04.011
6. Poirel L, Brinas L, Verlinde A et al. BEL-1, a novel clavulanic acidinhibited extended-spectrum beta-lactamase, and the class 1 integron In120 in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005;
49: 3743–8. https://doi.org/10.1128/AAC.49.9.3743-3748.2005
7. Talaro KP, Chess B. Foundations in microbiology. 8th ed. New York: McGraw Hill, 2008.
8. Abraham EP. Cephalosporins 1945-1986. Drugs 1987; 34 Suppl 2: 1–14. https://doi.org/10.2165/00003495-198700342-00003
9. Hamilton-Miller JM. Chemistry and biology of the polyene macrolide antibiotics. Bacteriol Rev 1973; 37: 166–96.
10. Mitscher LA. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem. Rev 2005; 105: 559–92. https://doi.org/10.1021/cr030101q
11. Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: an overview. Cold Spring Harb Perspect Med 2016; 6: a027029. https://doi. org/10.1101/cshperspect.a027029
12. Boyles TH, Naicker V, Rawoot N et al. Sustained reduction in antibiotic consumption in a South African public sector hospital; Four year outcomes from the Groote Schuur Hospital antibiotic stewardship program.
S Afr Med J 2017; 107: 115–8. https://doi.org/10.7196/SAMJ.2017.v107i2.12067
13. “WHO | WHO’s First Global Report on Antibiotic Resistance Reveals, Serious, Worldwide Threat to Public Health.” Who.Int, 22 September 2014. www.who.int/mediacentre/news/releases/2014/amr-report/en/, /entity/mediacentre/news/releases/2014/amr-report/en/index.html (15 August 2020, date last accessed).
14. Alghadeer S, Aljuaydi K, Babelghaith S et al. Self-medication with antibiotics in Saudi Arabia. Saudi Pharm J 2018; 26: 719–24. https://doi. org/10.1016/j.jsps.2018.02.018
15. Lieberthal AS, Carroll AE, Chonmaitree T et al. The diagnosis and management of acute otitis media. Pediatrics 2004; 113: 1451–65. https://doi.org/10.1542/peds.2012-3488
16. “Error.” Www.Moh.Gov.Sa, www.moh.gov.sa/en/CCC/healthp/regulations/Documents/National%20Antimicrobial%20%20Guidelines.pdf.
(15 August 2020, date last accessed).
17. Scott LJ, Ormrod D, Goa KL. Cefuroxime axetil: an updated review of its use in the management of bacterial infections. Drugs 2001; 61: 1455–500. https://doi.org/10.2165/00003495-200161100-00008
18. Vergis EN, Indorf A, File TM Jr et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med 2000; 160: 1294–300. https://doi.org/10.1001/ archinte.160.9.1294
19. Perry CM, Scott LJ. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections. Drugs 2004; 64: 1433–64. https:// doi.org/10.2165/00003495-200464130-00004
20. Chen L, Liu HG, Liu W et al. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43: E005. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0005
21. Zwane SP, McGee SM, Suleman F. et al. A comparative cost analysis of antibiotic treatment for Community Acquired Pneumonia (CAP) in adult inpatients at Piggs peak government hospital in Swaziland. Front Public
Health 2018; 6: 303. https://doi.org/10.3389/fpubh.2018.00303.